15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
32 citations
,
July 2001 in “Endocrine Practice” Insulin-sensitizing drugs like metformin can help with ovulation, weight loss, and lower testosterone in some women with PCOS.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
8 citations
,
May 2017 in “Singapore Medical Journal” A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
November 2023 in “Expert Opinion on Pharmacotherapy” Finasteride and dutasteride are effective in treating male hair loss but can cause sexual side effects and birth defects.
2 citations
,
March 2016 in “The Journal of Urology” Finasteride 1mg linked to diverse symptoms; other treatments improve erectile function in rats.
May 2024 in “Deleted Journal” Cancer treatments can cause hair loss, but it is often reversible and can be managed with scalp cooling and support.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
2 citations
,
January 1984 in “PubMed” Cimetidine does not significantly reduce hair growth in hirsutism.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than metformin in reducing type 2 diabetes risk in women with PCOS.
70 citations
,
March 2010 in “The Journal of Steroid Biochemistry and Molecular Biology” Blocking a specific enzyme might help treat obesity and diabetes, but more research is needed to ensure it's safe.
17 citations
,
August 2002 in “AIDS” Indinavir and ritonavir therapy can cause reversible hair loss.
11 citations
,
March 2019 in “Journal of Medicinal Chemistry” Some synthetic carbohydrate receptors, especially compounds 3 and 15, show strong potential for treating Zika virus.
66 citations
,
April 2017 in “International Journal of Andrology” Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
October 2021 in “Revista Medicina Cutánea Ibero-Latino-Americana” PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
December 2018 in “Actas urológicas españolas” 5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.
54 citations
,
February 1994 in “Journal of Investigative Dermatology” January 1978 in “Enlighten: Theses (The University of Glasgow)” Inhibiting testosterone 5alpha-reductase may help treat benign prostatic hyperplasia.
3 citations
,
January 2011 in “Annals of Dermatology” Blocking EGFR in skin cells doesn't majorly increase inflammation markers.
November 2011 in “ChemInform” June 2025 in “British Journal of Dermatology” JAK inhibitors help regrow hair in alopecia areata, but their long-term safety is still unclear.
September 2025 in “Obstetrics and gynecology.” Myoinositol effectively manages PCOS with fewer side effects than metformin.
August 2006 in “JNCI Journal of the National Cancer Institute”
November 2025 in “Eurasian journal of applied biotechnology” Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.
32 citations
,
June 2017 in “Journal of Pharmaceutical Sciences” Chitosan-coated nanoparticles improve skin delivery of hair loss treatments with fewer side effects.
January 2022 in “Drugs of Today”
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
January 2023 in “CINECA IRIS Institutial research information system (University of Pisa)” The composition helps treat hair loss.
March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.